On 22 July 2026, Medtas announced that it has launched a new in-pharmacy program (myMedtas-Care), following the 1 July 2026 listing of Wezlana®, biosimilar to Janssen’s Stelara® (ustekinumab), on the Australian Pharmaceutical Benefits Scheme (PBS). The in-pharmacy program allows credentialled community pharmacists to administer subcutaneous Wezlana® injections for patients.
Wezlana® is manufactured by Amgen and is the first ustekinumab biosimilar in Australia to be PBS-listed across all product formats of the originator. It is currently listed in 130 mg and 45 mg vial, and 45 mg and 90 mg pre-filled syringe, presentations.
The only other ustekinumab biosimilar currently PBS-listed in Australia is Celltrion’s Steqeyma® (1 August 2025). Steqeyma® is not PBS listed in the 45 mg vial presentation.
Samsung Bioepis’ Epyztek® (ustekinumab) was recommended for PBS listing at PBAC’s March 2025 meeting, but has not yet progressed to PBS listing, pending lodgement of required documentation. Sandoz’s Ardelya® (ustekinumab) was recommended for PBS listing at the March 2026 PBAC meeting but is yet to receive marketing approval in Australia.